Key Takeaway: Werewolf Therapeutics, based in Watertown, Massachusetts, has announced its financial results for the first quarter of 2026. The report includes insights into the company's performance and recent corporate developments. This update is significant for stakeholders and investors monitoring Werewolf's progress in the biopharma sector.
Price reaction · baseline $0.6265 (2026-05-07T17:16:00.000Z) · hit during market hours · clean, no other HOWL news in the window
day 0 close · peak
-1%
Market Sentiment Analysis
POSITIVE FACTORS
Werewolf Therapeutics reported financial results for Q1 2026.
The company provided recent corporate updates.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+25%
120-day peak, hindsight
Typical move
15%
average across 6 past catalysts
Lead asset
WTX-330
Phase 1 · Advanced or Metastatic Solid Tumors
Full Press Release Details
May 7, 2026
Werewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Updates
WATERTOWN, Mass., May 7, 2026 — Werewolf Therapeutics, Inc. (the "Company" or "Werewolf")
Share this article:
facebook-icon
twitter-icon
linked-in-icon
Frequently Asked Questions
What financial results did Werewolf report for Q1 2026?
Werewolf Therapeutics reported its financial results for the first quarter of 2026.
Where is Werewolf Therapeutics located?
Werewolf Therapeutics is based in Watertown, Massachusetts.
What updates did Werewolf provide in the report?
The report includes recent corporate updates alongside the financial results.